Remission of disseminated cancer after systemic oncolytic virotherapy

Stephen J Russell, Mark J Federspiel, Kah-Whye Peng, Caili Tong, David M Dingli, William G. Morice, Val Lowe, Michael K. O'Connor, Robert A. Kyle, Nelson Leung, Francis K. Buadi, S Vincent Rajkumar, Morie Gertz, Martha Lacy, Angela Dispenzieri

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

Original languageEnglish (US)
Pages (from-to)926-933
Number of pages8
JournalMayo Clinic Proceedings
Volume89
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Oncolytic Virotherapy
Plasmacytoma
Multiple Myeloma
Oncolytic Viruses
Neoplasms
Measles virus
Measles
Intravenous Infusions
Bone Marrow
Viruses
Gene Expression
Glucose
Therapeutics
Infection
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Remission of disseminated cancer after systemic oncolytic virotherapy. / Russell, Stephen J; Federspiel, Mark J; Peng, Kah-Whye; Tong, Caili; Dingli, David M; Morice, William G.; Lowe, Val; O'Connor, Michael K.; Kyle, Robert A.; Leung, Nelson; Buadi, Francis K.; Rajkumar, S Vincent; Gertz, Morie; Lacy, Martha; Dispenzieri, Angela.

In: Mayo Clinic Proceedings, Vol. 89, No. 7, 2014, p. 926-933.

Research output: Contribution to journalArticle

@article{7a70b70df03349e0829053239ef355f9,
title = "Remission of disseminated cancer after systemic oncolytic virotherapy",
abstract = "MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50{\%} tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.",
author = "Russell, {Stephen J} and Federspiel, {Mark J} and Kah-Whye Peng and Caili Tong and Dingli, {David M} and Morice, {William G.} and Val Lowe and O'Connor, {Michael K.} and Kyle, {Robert A.} and Nelson Leung and Buadi, {Francis K.} and Rajkumar, {S Vincent} and Morie Gertz and Martha Lacy and Angela Dispenzieri",
year = "2014",
doi = "10.1016/j.mayocp.2014.04.003",
language = "English (US)",
volume = "89",
pages = "926--933",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Remission of disseminated cancer after systemic oncolytic virotherapy

AU - Russell, Stephen J

AU - Federspiel, Mark J

AU - Peng, Kah-Whye

AU - Tong, Caili

AU - Dingli, David M

AU - Morice, William G.

AU - Lowe, Val

AU - O'Connor, Michael K.

AU - Kyle, Robert A.

AU - Leung, Nelson

AU - Buadi, Francis K.

AU - Rajkumar, S Vincent

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

PY - 2014

Y1 - 2014

N2 - MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

AB - MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 1011 TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone-marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved with in the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.

UR - http://www.scopus.com/inward/record.url?scp=84904744363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904744363&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2014.04.003

DO - 10.1016/j.mayocp.2014.04.003

M3 - Article

C2 - 24835528

AN - SCOPUS:84904744363

VL - 89

SP - 926

EP - 933

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -